KASH5 and neoplasm: By finding a tumor-resident B lymphoblastoid cell line with CCDC155 specificity, and by revealing antibodies in almost half of a small cohort of patients (Figure 6), our results confirm CCDC155 is a tumor-associated antigen in EOC and point to its continued antigenicity into late-stage, primary and recurrent disease.